We can't find the internet
Attempting to reconnect
17517.2 PFLS-LS
17517.2 PFLS-LS
Zusammenfassung
Anti-cancer efficacy and mode of action dissection of a novel first-in class inhibitor of the Notch pathway
Weitere Texte
Abstract
Cellestia Biotech is developing first-in class oral small molecule inhibitor of the Notch pathway with a mechanism of action completely different from current therapies(GSIs and Mabs) in development to target this pathway. |The goal of this project is:|i) To dissect the mechanism of action of the novel inhibitor of Notch at molecular level.|ii) To explore the invivo anti-tumor efficacy, with a focus on Notch driven cancers that cannot be adressed by the current therapies.|
Beteiligte
Rajwinder Lehal
Wirtschaftspartner
raj.lehal@cellestia.com
Cellestia Biotech AG CHE-162.364.457 Rajwinder Lehal Hochbergerstr. 60C 4057 Basel BS CH
Freddy Radtke
Kontaktperson
freddy.radtke@epfl.ch
EPFL SV ISREC UPRAD Life Science Faculty Freddy Radtke Station 19 1015 Lausanne VD CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2015-03-31
- Enddatum
- 2016-09-30
- Bewilligte Gesamtkosten
- CHF 250056.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%